TrialPath
Recruiting

A Study to Assess the Efficacy, Safety and Tolerability of DDY391 in Participants With Moderate to Severe Psoriatic Arthritis

NCT07801495 · Novartis
In plain English

Click the button to translate this study into plain language — what it is, who qualifies, and what participation looks like.

Official title
A Randomized, Double-blind, Placebo-controlled, Multicenter Phase 2a/b Study Assessing the Efficacy, Safety and Tolerability of DDY391 in Participants With Active Moderate to Severe Psoriatic Arthritis
About this study
This study is a Phase 2a/b, randomized, double-blind, placebo-controlled, multicenter trial designed to evaluate the efficacy, safety, tolerability and dose-response relationship of DDY391 in participants with active moderate to severe PsA. The study is composed of two sequential parts: * Part A to evaluate efficacy, safety and tolerability of DDY391 compared with placebo. * Part B to determine the dose-response relationship of multiple doses of DDY391 compared with placebo.
Eligibility criteria
Key Inclusion Criteria: * Female or male participants at least 18 years of age. * Diagnosis of PsA and meeting classification criteria for Psoriatic arthritis (CASPAR) at screening. * Moderate to severe PsA at screening and baseline. Key Exclusion Criteria: * Presence of inflammatory conditions other than psoriasis or PsA including but not limited to those associated with arthralgia or arthritis (e.g., rheumatoid arthritis, systemic lupus erythematosus, scleroderma, sarcoidosis) or presence of fibromyalgia or osteoarthritis with articular symptoms. * Use of bDMARD treatment within 4 weeks or 5 half-lives of randomization, whichever is longer * Prior use of JAK inhibitors or TYK2 inhibitors (e.g., deucravacitinib). Prior use of apremilast is allowed but must not be taken within 4 weeks of baseline. * Previous treatment with any cell-depleting therapies, including but not limited to anti-CD20, unless ≥ 12 months prior to baseline. * History of lymphoproliferative disease or any known malignancy or history of malignancy of any organ system within the past 5 years (except for basal cell carcinoma or actinic keratosis that have been treated with no evidence of recurrence in the past 3 months, carcinoma in situ of the cervix or non-invasive malignant colon polyps that have been removed). * Any active viral, bacterial or other infections at the time of screening or randomization, or history of recurrent clinically significant infection or of recurrent bacterial infections. Other protocol-defined inclusion/exclusion criteria may apply.
Study design
Enrollment target: 220 participants
Allocation: randomized
Masking: double
Age groups: adult, older_adult
Timeline
Starts: 2026-10-19
Estimated completion: 2029-01-12
Last updated: 2026-11-09
Interventions
Drug: DDY391Drug: Placebo
Primary outcomes
  • • Part A: Number of participants achieving American College of Rheumatology 50 (ACR50) response (Week 12)
  • • Part A and B: Number of participants achieving American College of Rheumatology 50 (ACR50) response (Week 12)
Sponsor
Novartis Pharmaceuticals · industry
Contacts & investigators
ContactNovartis Pharmaceuticals · contact · novartis.email@novartis.com · 1-888-669-6682
ContactNovartis Pharmaceuticals · contact · +41613241111
All locations (8)
Newport Huntington Medical GroupRecruiting
Huntington Beach, California, United States
Altoona Center for Clin ResRecruiting
Duncansville, Pennsylvania, United States
WCG CR Philadelphia LLCRecruiting
Philadelphia, Pennsylvania, United States
Shelby Research LLCRecruiting
Memphis, Tennessee, United States
Precision Comprehensive ResearchRecruiting
Colleyville, Texas, United States
Arthritis Care of TexasRecruiting
Corpus Christi, Texas, United States
Biopharma Informatic LLCRecruiting
Katy, Texas, United States
Rheumatology Associates of South TexasRecruiting
San Antonio, Texas, United States
A Study to Assess the Efficacy, Safety and Tolerability of DDY391 in Participants With Moderate to Severe Psoriatic Arthritis · TrialPath